Blood test detects thousands of fetal genetic conditions

Scientists have unveiled a new maternal blood test capable of detecting thousands of serious genetic conditions in a developing fetus, a breakthrough that could dramatically reduce the need for invasive prenatal screening. The technique, called noninvasive fetal sequencing (NIFS), analyzes fragments of fetal DNA circulating in a pregnant person's bloodstream to screen nearly 23,000 genes. The research was presented on Saturday, June 13, 2026, at the annual conference of the European Society of Human Genetics in Gothenburg, Sweden.

The test represents a major expansion of current noninvasive prenatal testing (NIPT), which is typically limited to detecting a small number of conditions like Down syndrome. NIFS aims to screen for almost all genetic conditions included in standard newborn screenings and fetal anomaly panels. Dr. Christopher Whelan, a senior computational scientist at the Broad Institute of MIT and Harvard who presented the findings, said the test is capable of detecting thousands of serious genetic conditions, including the majority found on major diagnostic panels. Examples from the validation study include Noonan syndrome, cystic fibrosis, and achondroplasia.